BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1290 related articles for article (PubMed ID: 24048897)

  • 1. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
    Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
    J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmacytoid dendritic cells induce efficient stimulation of antiviral immunity in the context of chronic hepatitis B virus infection.
    Martinet J; Leroy V; Dufeu-Duchesne T; Larrat S; Richard MJ; Zoulim F; Plumas J; Aspord C
    Hepatology; 2012 Nov; 56(5):1706-18. PubMed ID: 22707082
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
    Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
    Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
    Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
    Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
    Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
    Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nasal route favors the induction of CD4
    Bourgine M; Crabe S; Lobaina Y; Guillen G; Aguilar JC; Michel ML
    Antiviral Res; 2018 May; 153():23-32. PubMed ID: 29510155
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lentiviral vector encoding ubiquitinated hepatitis B core antigen induces potent cellular immune responses and therapeutic immunity in HBV transgenic mice.
    Dai S; Zhuo M; Song L; Chen X; Yu Y; Zang G; Tang Z
    Immunobiology; 2016 Jul; 221(7):813-21. PubMed ID: 26874581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clearing Persistent Extracellular Antigen of Hepatitis B Virus: An Immunomodulatory Strategy To Reverse Tolerance for an Effective Therapeutic Vaccination.
    Zhu D; Liu L; Yang D; Fu S; Bian Y; Sun Z; He J; Su L; Zhang L; Peng H; Fu YX
    J Immunol; 2016 Apr; 196(7):3079-87. PubMed ID: 26936879
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
    Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
    Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis B surface antigen (HBsAg) and core antigen (HBcAg) combine CpG oligodeoxynucletides as a novel therapeutic vaccine for chronic hepatitis B infection.
    Li J; Ge J; Ren S; Zhou T; Sun Y; Sun H; Gu Y; Huang H; Xu Z; Chen X; Xu X; Zhuang X; Song C; Jia F; Xu A; Yin X; Du SX
    Vaccine; 2015 Aug; 33(35):4247-54. PubMed ID: 25858855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Overcoming HBV immune tolerance to eliminate HBsAg-positive hepatocytes via pre-administration of GM-CSF as a novel adjuvant for a hepatitis B vaccine in HBV transgenic mice.
    Wang X; Dong A; Xiao J; Zhou X; Mi H; Xu H; Zhang J; Wang B
    Cell Mol Immunol; 2016 Nov; 13(6):850-861. PubMed ID: 26166767
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Therapeutic recovery of hepatitis B virus (HBV)-induced hepatocyte-intrinsic immune defect reverses systemic adaptive immune tolerance.
    Lan P; Zhang C; Han Q; Zhang J; Tian Z
    Hepatology; 2013 Jul; 58(1):73-85. PubMed ID: 23447417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Kupffer cell-derived IL-10 plays a key role in maintaining humoral immune tolerance in hepatitis B virus-persistent mice.
    Xu L; Yin W; Sun R; Wei H; Tian Z
    Hepatology; 2014 Feb; 59(2):443-52. PubMed ID: 23929689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protein-prime/modified vaccinia virus Ankara vector-boost vaccination overcomes tolerance in high-antigenemic HBV-transgenic mice.
    Backes S; Jäger C; Dembek CJ; Kosinska AD; Bauer T; Stephan AS; Dišlers A; Mutwiri G; Busch DH; Babiuk LA; Gasteiger G; Protzer U
    Vaccine; 2016 Feb; 34(7):923-32. PubMed ID: 26776470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune tolerance against HBV can be overcome in HBV transgenic mice by immunization with dendritic cells pulsed by HBVsvp.
    Farag MM; Tedjokusumo R; Flechtenmacher C; Asen T; Stremmel W; Müller M; Protzer U; Weigand K
    Vaccine; 2012 Sep; 30(42):6034-9. PubMed ID: 22867720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. γδT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance.
    Kong X; Sun R; Chen Y; Wei H; Tian Z
    J Immunol; 2014 Aug; 193(4):1645-53. PubMed ID: 25015833
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Breaking tolerance leads to autoantibody production but not autoimmune liver disease in hepatitis B virus envelope transgenic mice.
    Wirth S; Guidotti LG; Ando K; Schlicht HJ; Chisari FV
    J Immunol; 1995 Mar; 154(5):2504-15. PubMed ID: 7868916
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Optimization of immune responses induced by therapeutic vaccination with cross-reactive antigens in a humanized hepatitis B surface antigen transgenic mouse model.
    Bourgine M; Dion S; Godon O; Guillen G; Michel ML; Aguilar JC
    Virology; 2012 Aug; 430(1):10-9. PubMed ID: 22591777
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunizations with hepatitis B viral antigens and a TLR7/8 agonist adjuvant induce antigen-specific immune responses in HBV-transgenic mice.
    Wang Y; Chen K; Wu Z; Liu Y; Liu S; Zou Z; Chen SH; Qu C
    Int J Infect Dis; 2014 Dec; 29():31-6. PubMed ID: 25449231
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The delivery of HBcAg via Tat-PTD enhances specific immune response and inhibits Hepatitis B virus replication in transgenic mice.
    Chen X; Lai J; Pan Q; Tang Z; Yu Y; Zang G
    Vaccine; 2010 May; 28(23):3913-9. PubMed ID: 20394723
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 65.